WHO raises Ebola risk level in DR Congo to 'very high'
Story essentials
World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus
Democratic Republic of Congo
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRead next
Prioritized by shared people, places, and events.
Oxford University begins clinical trials for Bundibugyo Ebola vaccine
Oxford University has administered the first dose of a vaccine targeting the Bundibugyo strain of Ebola. The outbreak in DRC and Uganda has caused over 1,270 deaths and nearly 3,000 infections since May. The vaccine candidate was developed in eight weeks using technology similar to the AstraZeneca Covid-19 vaccine. WHO warns that the actual number of cases could be twice as high due to conflict-related access issues.
Related book
The Coming Plague: Newly Emerging Diseases in a World Out of Balance
Author: Laurie Garrett
Laurie Garrett provides a comprehensive look at how environmental degradation, social instability, and global connectivity facilitate the spread of emerging pathogens like Ebola, offering deep insight into why conflict-ridden regions become hotspots for outbreaks.
As an Amazon Associate, COMPAMIR earns from qualifying purchases.